{"id":"pre-radiotherapy-commencement-of-anastrozole","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Hot flashes"},{"rate":"15-25%","effect":"Joint pain"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1399","moleculeType":"Small molecule","molecularWeight":"293.37"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Anastrozole is a selective aromatase inhibitor that blocks the conversion of androgens to estrogens, thereby lowering circulating estrogen levels which can slow the growth of hormone-sensitive breast cancer cells.","oneSentence":"Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:52.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer"},{"name":"Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy"}]},"trialDetails":[{"nctId":"NCT00887380","phase":"PHASE3","title":"STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)","status":"UNKNOWN","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2009-09-16","conditions":"Breast Cancer","enrollment":2023},{"nctId":"NCT03948568","phase":"PHASE4","title":"Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2019-09-17","conditions":"Early-stage Breast Cancer","enrollment":262},{"nctId":"NCT01402193","phase":"PHASE3","title":"Study of Arimidex and Radiotherapy Sequencing","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-07","conditions":"Breast Cancer","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arimidex"],"phase":"phase_3","status":"active","brandName":"Pre-radiotherapy commencement of anastrozole","genericName":"Pre-radiotherapy commencement of anastrozole","companyName":"Trans Tasman Radiation Oncology Group","companyId":"trans-tasman-radiation-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women. Used for Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}